Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Coeur Commences Drilling at Silver North's Tim Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Delcath Systems Inc DCTH

Healthcare Medical Devices Diagnostics & Research
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while... see more

Recent & Breaking News (NDAQ:DCTH)

Delcath to Present at 30th Annual Roth Conference

GlobeNewswire March 12, 2018

OTCQX And OTCQB Companies to Present At 2018 ROTH Conference

PR Newswire March 8, 2018

Delcath Announces Commercial Supply Agreement for Melphalan Hydrochloride for Injection with Tillomed Laboratories

GlobeNewswire March 7, 2018

Delcath Announces 500th Commercial CHEMOSAT Treatment in Europe

GlobeNewswire February 2, 2018

Delcath Announces Satisfaction of 2016 Convertible Note

GlobeNewswire February 1, 2018

Delcath Announces Special Protocol Agreement Modification With FDA

GlobeNewswire January 10, 2018

Positive Results From a Multi-Center Analysis of Delcath PHP Therapy Published in Journal of Surgical Oncology

GlobeNewswire January 9, 2018

Delcath Announces Exit from Convertible Note

GlobeNewswire December 29, 2017

Delcath Announces Preliminary Safety Analysis for Phase 3 Focus Trial  

GlobeNewswire December 19, 2017

Favorable Results from a Multi-Center Analysis of Delcath PHP Therapy to be Published in Journal of Surgical Oncology

GlobeNewswire December 5, 2017

Delcath Enhances Board of Directors With Appointment of Industry Veteran, Dr. Simon Pedder

GlobeNewswire November 20, 2017

Delcath Announces Third Quarter 2017 Financial Results

GlobeNewswire November 14, 2017

Delcath Announces Accelerated Listing on OTCQB

GlobeNewswire September 14, 2017

Delcath Announces Relisting on OTCQB

GlobeNewswire September 13, 2017

Delcath Issues Letter to Stockholders

GlobeNewswire September 1, 2017

Technical Snapshots for these Drug Delivery Stocks -- Delcath Systems, Valeant Pharma, PetMed Express, and Adamis Pharma

PR Newswire September 1, 2017

Delcath Announces Medical University of Hannover in Germany Celebrates 100th CHEMOSAT Treatment

GlobeNewswire August 29, 2017

Delcath Announces Agreement for Extinguishment of Convertible Notes with Majority Holder

GlobeNewswire August 28, 2017

Delcath Systems, Inc. Announces Extension of Expiration Date of its Consent Solicitation and Ability to Change Consent Once Voted

GlobeNewswire August 22, 2017

Delcath Announces Second Quarter 2017 Financial Results

PR Newswire August 8, 2017